<DOC>
	<DOC>NCT02054130</DOC>
	<brief_summary>The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 18 through 75 BMI between 1840 kg/m2 and weight greater than or equal 40 kg Documented physiciandiagnosed asthma Subjects must have received a physicianprescribed asthma controller regimen with medium or highdose ICS plus LABA If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, LAMA, cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit. Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma. Current smokers or subjects with a smoking history of â‰¥ 10 pack years Former smokers with &lt; 10 pack years must have stopped for at least 1 year to be eligible. Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (eg, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, ChurgStrauss syndrome). Evidence of active liver disease. History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed Known history of active tuberculosis (TB) History of anaphylaxis to any biologic therapy Positive medical history for hepatitis B or C Subject with HIV or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma</keyword>
</DOC>